Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

TCL1A polymorphism predicts AML progression in myeloid neoplasms

Alfonso Molina, Alexandria Jensen, Jayakrishnan Gopakumar, Vishesh Khanna, Henning Stehr, Siddhartha Jaiswal, Peter Greenberg

Blood (2025) 146 (Supplement 1): 3854.

https://doi.org/10.1182/blood-2025-3854

Published: 2025

Journal Articles

Double-dose axicabtagene ciloleucel (Axi-Cel-2) as second-line therapy for high-risk relapsed or refractory large B-cell lymphoma (r/rLBCL): Interim results from a Phase 1b study

Blood (2025) 146 (Supplement 1): 671.

https://doi.org/10.1182/blood-2025-671

Published: 2025

Journal Articles

Validated PET-CT metabolic tumor volume threshold identifies high-risk relapsed/refractory LBCL and predicts 12-month toxicity-free progression-free survival Post–CAR-T therapy

Blood (2025) 146 (Supplement 1): 397.

https://doi.org/10.1182/blood-2025-397

Published: 2025

Journal Articles

Evaluating thymic stromal lymphopoietin (TSLP) as a biomarker in acute graft versus host disease

Blood (2025) 146 (Supplement 1): 586.

https://doi.org/10.1182/blood-2025-586

Published: 2025

Journal Articles

Rapid peak CAR-T expansion is associated with delayed neurotoxicity following ciltacabtagene autoleucel in multiple myeloma

Blood (2025) 146 (Supplement 1): 96.

https://doi.org/10.1182/blood-2025-96

Published: 2025

Journal Articles

From response to rupture: Evaluating GI perforation after CD19 CAR‑T in LBCL

Arash Velayati, Masooma Rana, Alexandria Jensen, Dasom (Caroline) Lee, Nima Ghalehsari, Anmol Goyal, Theresa Latchford, William Wang, Eric Heng, Wen-Kai Weng, Melody Smith, Sushma Bharadwaj, Matthew Frank, David Miklos, Saurabh Dahiya

Blood (2025) 146 (Supplement 1): 2771.

https://doi.org/10.1182/blood-2025-2771

Published: 2025

Journal Articles

Association between cilta-cel dose and efficacy and toxicity outcomes for patients with Relapsed/Refractory multiple myeloma (RRMM): A real-world analysis from the US multiple myeloma immunotherapy consortium

Ran Reshef, Alexandria Jensen, Christian Gordillo, Brett Reid, Danai Dima, Lauren Peres, Mahmoud Gaballa, Rahul Banerjee, Oren Pasvolsky, Aimaz Afrough, Christen Dillard, Christopher Ferreri, Shebli Atrash, Cindy Varga, Andrew Portuguese, Masooma Rana, Hitomi Hosoya, Lekha Mikkilineni, Vanna Hovanky, Saurabh Zanwar, Nilesh Kalariya, Damian Mikulski, Charlotte Wagner, Christopher Cahoon, Omar Puglianini, Gabriel De Avila, Eli Zolotov, Evguenia Bhurtel, Ariel Grajales-Cruz, Utkarsh Goel, Aishwarya Sannareddy, Jeries Kort, Raffaella Cassano, Shonali Midha, James Davis, Rebecca Gonzalez, Megan Herr, Zhuoer Xie, Hamza Hassan, Sneha Purvey, Marcus Geer, Kimberly Green, Fabiana Perna, Hien Liu, Taiga Nishihori, Jack Khouri, Shahzad Raza, Faiz Anwer, Susan Bal, Omar Nadeem, Ciara Louise Freeman, Leyla Shune, Kenneth Shain, Melissa Alsina, Rachid Baz, Douglas Sborov, Saurabh Dahiya, Frederick Locke, David Miklos, Peter Voorhees, Larry Anderson, Luciano Costa, Noa Biran, Shaji Kumar, Yi Lin, Krina Patel, Doris Hansen, Surbhi Sidana

Blood (2025) 146 (Supplement 1): 134.

https://doi.org/10.1182/blood-2025-134

Published: 2025

Journal Articles

Safety and efficacy of BCMA directed CAR-T therapy in older patients (Aged ≥ 75) with relapsed or refractory multiple myeloma (RRMM)

Blood (2025) 146 (Supplement 1): 6375.

https://doi.org/10.1182/blood-2025-6375

Published: 2025

Journal Articles

Non-response to bridging therapy prior to CAR-T is associated with increased toxicity and adverse outcomes in Relapsed/Refractory multiple myeloma (RRMM)

Blood (2025) 146 (Supplement 1): 4586.

https://doi.org/10.1182/blood-2025-4586

Published: 2025

Journal Articles

Pre-treatment CD19 antigen density and multi-antigen profiling by calibrated quantitative flow cytometry correlates with CAR T efficacy in LBCL

Blood (2025) 146 (Supplement 1): 5882.

https://doi.org/10.1182/blood-2025-5882

Published: 2025

Journal Articles

Real-world outcomes of immune effector cell-associated hemophagocytic syndrome (IEC-HS) following ide-cel and cilta-cel therapy in relapsed/refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 719.

https://doi.org/10.1182/blood-2025-719

Published: 2025

Journal Articles

Optimal ferritin threshold to diagnose immune effector cell-associated hemophagocytic syndrome (IEC-HS) following CAR-T therapy in relapsed/refractory multiple myeloma (RRMM)

Blood (2025) 146 (Supplement 1): 717.

https://doi.org/10.1182/blood-2025-717

Published: 2025

Journal Articles

A subset of patients achieve prolonged remission beyond 3–5 years with FHVH33-CD8BBZ BCMA CAR T-cells for RRMM

Lekha Mikkilineni, Jennifer Mann, Genevieve Fromm, Alexandria Jensen, Micaela Ganadan, Danielle Natrakul, Jennifer Brudno, James Kochenderfer

Blood (2025) 146 (Supplement 1): 4162.

https://doi.org/10.1182/blood-2025-4162

Published: 2025

Journal Articles

Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy

Blood (2025) 146 (17): 2063–2072.

https://doi.org/10.1182/blood.2025029773

Published: 2025

Includes: Supplemental data

Journal Articles

Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy in Octogenarian Patients (Aged ≥ 80) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Blood (2024) 144 (Supplement 1): 386.

https://doi.org/10.1182/blood-2024-201822

Published: 2024

Journal Articles

Anti-BCMA CAR T-Cell Expansion and Its Association with Response and Toxicity in Multiple Myeloma

Blood (2024) 144 (Supplement 1): 2006.

https://doi.org/10.1182/blood-2024-211128

Published: 2024

Journal Articles

Talquetamab Bridging: Paving the Way to B-Cell Maturation Antigen (BCMA) CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM)

Blood (2024) 144 (Supplement 1): 931.

https://doi.org/10.1182/blood-2024-202017

Published: 2024

Journal Articles

Long-Term Efficacy and Immune Reconstitution with Bendamustine As a Lymphodepleting Agent for Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory or Relapsed Large B-Cell Lymphoma (LBCL)

Sushma Bharadwaj, Eric Lau, Anmol Goyal, Mark P. Hamilton, Hrishikesh Srinagesh, Alexandria Jensen, Shriya Syal, Jayasindhu Mallampet, Theresa Latchford, Bita Sahaf, Wen-Kai Weng, Melody Smith, Holden T Maecker, Matthew J. Frank, David B. Miklos, Saurabh Dahiya

Blood (2023) 142 (Supplement 1): 4878.

https://doi.org/10.1182/blood-2023-188166

Published: 2023

Journal Articles

Analysis of PET-CT Derived Radiomic Biomarkers with Efficacy, Safety, and Expansion of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL)

Blood (2023) 142 (Supplement 1): 2125.

https://doi.org/10.1182/blood-2023-187617

Published: 2023

Journal Articles

Impact of Obesity on Efficacy, Safety, and Expansion Kinetics of Chimeric Antigen Receptor-T (CAR T) Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma (LBCL)

Anmol Goyal, Sushma Bharadwaj, Dasom Lee, Eric Lau, Mark P. Hamilton, Alexandria Jensen, Bita Sahaf, Shriya Syal, Sunita Patil, Juancarlos E Cancilla, Theresa Latchford, Wen-Kai Weng, Melody Smith, Matthew J. Frank, David B. Miklos, Saurabh Dahiya

Blood (2023) 142 (Supplement 1): 3783.

https://doi.org/10.1182/blood-2023-186828

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Date

Availability

TCL1A polymorphism predicts AML progression in myeloid neoplasms

Double-dose axicabtagene ciloleucel (Axi-Cel-2) as second-line therapy for high-risk relapsed or refractory large B-cell lymphoma (r/rLBCL): Interim results from a Phase 1b study

Validated PET-CT metabolic tumor volume threshold identifies high-risk relapsed/refractory LBCL and predicts 12-month toxicity-free progression-free survival Post–CAR-T therapy

Evaluating thymic stromal lymphopoietin (TSLP) as a biomarker in acute graft versus host disease

Rapid peak CAR-T expansion is associated with delayed neurotoxicity following ciltacabtagene autoleucel in multiple myeloma

From response to rupture: Evaluating GI perforation after CD19 CAR‑T in LBCL

Association between cilta-cel dose and efficacy and toxicity outcomes for patients with Relapsed/Refractory multiple myeloma (RRMM): A real-world analysis from the US multiple myeloma immunotherapy consortium

Safety and efficacy of BCMA directed CAR-T therapy in older patients (Aged ≥ 75) with relapsed or refractory multiple myeloma (RRMM)

Non-response to bridging therapy prior to CAR-T is associated with increased toxicity and adverse outcomes in Relapsed/Refractory multiple myeloma (RRMM)

Pre-treatment CD19 antigen density and multi-antigen profiling by calibrated quantitative flow cytometry correlates with CAR T efficacy in LBCL

Real-world outcomes of immune effector cell-associated hemophagocytic syndrome (IEC-HS) following ide-cel and cilta-cel therapy in relapsed/refractory multiple myeloma

Optimal ferritin threshold to diagnose immune effector cell-associated hemophagocytic syndrome (IEC-HS) following CAR-T therapy in relapsed/refractory multiple myeloma (RRMM)

A subset of patients achieve prolonged remission beyond 3–5 years with FHVH33-CD8BBZ BCMA CAR T-cells for RRMM

Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy

Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy in Octogenarian Patients (Aged ≥ 80) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Anti-BCMA CAR T-Cell Expansion and Its Association with Response and Toxicity in Multiple Myeloma

Talquetamab Bridging: Paving the Way to B-Cell Maturation Antigen (BCMA) CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM)

Long-Term Efficacy and Immune Reconstitution with Bendamustine As a Lymphodepleting Agent for Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory or Relapsed Large B-Cell Lymphoma (LBCL)

Analysis of PET-CT Derived Radiomic Biomarkers with Efficacy, Safety, and Expansion of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL)

Impact of Obesity on Efficacy, Safety, and Expansion Kinetics of Chimeric Antigen Receptor-T (CAR T) Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma (LBCL)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only